Actinium-225 is a promising therapeutic isotope drawing significant interest in targeted radiopharmaceutical therapy. Bringing it to scale is one of the defining infrastructure challenges in oncology today. Serva exists to solve that challenge with a production path built to scale without the years-long lead times and millions in capital that new dedicated facilities typically require.